ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Nov 2015 Pooled analysis results of ARMOR I and ARMOR II published in the Clinical cancer research: an official journal of the American Association for Cancer Research
04 Mar 2013 Results will be presented at the 2013 International Congress on Targeted Anticancer Therapies (TAT), according to a Tokai Pharmaceuticals media release.
01 Jun 2012 Results were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in 2012.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com